ACLX - שווי פעילות לרווח לפני ריבית, מסים ופחת arcellx.com

Supply chain disruption risks are forcing Arcellx (ACLX) to rely on strategic production outsourcing, a trend reflected in the EV/EBITDA multiple on the GURU.Markets terminal chart, where the parameter is 0.00. The broader picture is complemented by a fierce struggle with pharma behemoths for priority in the approval of cell technologies, which determines the market value of this biotech asset.

This ratio compares the total enterprise value, including net debt, to operating profit before depreciation and amortization, determining the asset's real value relative to its ability to generate cash flow. For Arcellx (ACLX), whose growth depends on the commercialization of CAR-T therapy, the EV/EBITDA metric for this capital-intensive business reflects market expectations for future drug sales, warning investors of the risk of company overvaluation.